New immunotherapy cocktail targets Hard-to-Treat cancers
NCT ID NCT06247956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants with unresectable or metastatic disease will receive the combination. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-8068 (an experimental immunotherapy drug) combined with adebrelimab (another immunotherapy) and platinum-based chemotherapy
- What this could lead to
- If successful, this could lead to a new first-line treatment option that shrinks tumors more effectively in advanced gastric and esophageal cancers.
- What could go wrong
- This is an early Phase 2 trial with only 153 participants, so results may not apply to all patients. The combination may cause significant side effects from immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- New pill combo aims to fight stomach cancer when first treatment fails
- Engineered immune cells take on stomach cancer in early trial
- Stomach cancer hope: new combo targets tumors after PD-1 failure
- Glowing dye may guide surgeons during stomach cancer operations